← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

BEST1 Bestrophinopathies

MONDO:0000390 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 47 citations openscientist · 52 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

Bestrophinopathies are caused by pathogenic variants in BEST1, which encodes bestrophin-1, a pentameric calcium-activated chloride channel expressed on the basolateral membrane of the retinal pigment epithelium (RPE).

UNANIMOUS INTEGRATED
pathophysiologygene_functiongenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 95% a homopentameric Ca2+-activated anion (chloride) channel expressed in RPE
Falcon states the same core molecular identity of bestrophin-1 as a homopentameric Ca2+-activated anion channel expressed in RPE.
DOI:10.4103/sjopt.sjopt_175_23
openscientist CONCORDANT 97% which encodes bestrophin-1, a pentameric calcium-activated chloride channel (CaCC) predominantly expressed on the basolateral membrane of the retinal pigment epithelium (RPE)
OpenScientist matches the pentameric CaCC identity and adds the specific basolateral-membrane localization.
PMID:25324390, PMID:25878489

BEST1 variants produce a phenotypic spectrum of clinically distinct inherited retinal dystrophies — BVMD, ARB, ADVIRC, BEST1-associated retinitis pigmentosa (RP50), and adult-onset vitelliform macular dystrophy — with dominant and recessive forms representing a single disease continuum.

MAJORITY INTEGRATED
phenotypegenetic_factor
ProviderStanceScoreEvidence
openscientist CONCORDANT 95% giving rise to five clinically distinct phenotypes: Best Vitelliform Macular Dystrophy (BVMD; OMIM #153700), Autosomal Recessive Bestrophinopathy (ARB; OMIM #611809), Autosomal Dominant Vitreoretinochoroidopathy (ADVIRC; OMIM #193220), Retinitis Pigmentosa type 50 (RP50; OMIM #613194), and Adult-Onset Vitelliform Macular Dystrophy (AVMD)
OpenScientist explicitly enumerates the five recognized phenotypes with OMIM identifiers.
falcon PARTIAL 60% BEST1 pathogenic variants cause a phenotypic spectrum collectively termed
Falcon frames the disorders as a BEST1 phenotypic spectrum and describes the subtypes across a comparison table, but reclassifies adult-onset vitelliform cases into BVMD rather than enumerating a fixed set of five, so its subtype membership is framed differently.
DOI:10.4103/sjopt.sjopt_175_23

The two genetic mechanism classes differ by inheritance: dominant forms (BVMD, ADVIRC) act largely by a dominant-negative effect through incorporation of mutant subunits into the pentameric channel, whereas recessive forms (ARB, RP50) are biallelic loss-of-function.

UNANIMOUS INTEGRATED
genetic_factorpathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 80% enabled by pentameric co-assembly
Falcon classifies BEST1 variants into loss-of-function, dominant-negative (enabled by pentameric co-assembly poisoning wild-type complexes), and gain-of-function categories, matching the dominant-negative-vs-LOF split.
DOI:10.4103/sjopt.sjopt_175_23
openscientist CONCORDANT 90% In dominant forms, mutant bestrophin-1 exerts dominant-negative effects on pentameric channel assembly
OpenScientist asserts the dominant-negative mechanism for dominant forms and biallelic loss-of-function for recessive forms.
PMID:41456629

Bestrophin-1 dysfunction disrupts RPE chloride conductance and calcium homeostasis, impairing transepithelial fluid transport and phagocytosis of photoreceptor outer segments, causing subretinal fluid and vitelliform/lipofuscin material accumulation and progressive photoreceptor degeneration and macular atrophy.

UNANIMOUS INTEGRATED
pathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 90% RPE support failure contributes to accumulation of subretinal material, fluid dysregulation (subretinal/intraretinal fluid), and progressive outer retinal disruption leading to photoreceptor dysfunction/degeneration and macular atrophy.
Falcon lays out the same downstream causal chain from RPE support failure to photoreceptor degeneration and macular atrophy.
openscientist CONCORDANT 90% leading to impaired transepithelial fluid transport, defective phagocytosis of photoreceptor outer segments, accelerated lipofuscin accumulation, and progressive vitelliform material deposition at the macula
OpenScientist gives the parallel causal chain and adds the impaired-phagocytosis and lipofuscin-accumulation steps, supported by iPSC-RPE data.
PMID:32882766, PMID:29540715

A protein-quality-control mechanism degrades certain mutant bestrophin-1 proteins (p.P233L, p.P346H) via Hsp70/CHIP-mediated ubiquitination at Lys149, preventing membrane localization and reducing chloride channel activity.

SINGLE LEAD
pathophysiologygene_function
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Lys149 was identified as the site responsible for ubiquitination of p.P346H- and p.P233L-bestrophin-1, mediated by Hsp70 and the C-terminal Hsp70-interacting protein (CHIP).
OpenScientist details the Hsp70/CHIP ubiquitination-and-degradation mechanism, validated in MDCK II cells and zebrafish.
PMID:41456629
falcon SILENT —
Falcon does not describe the Hsp70/CHIP ubiquitination pathway; its dominant-negative account stops at pentameric co-assembly and trafficking without this degradation detail.

A structure-guided small-molecule strategy exists: PABA (4-aminobenzoic acid) binds an extracellular allosteric site and activates Best1, rescuing currents of multiple dominant loss-of-function patient mutants in vitro.

SINGLE LEAD
treatmentgene_function
ProviderStanceScoreEvidence
falcon CONCORDANT 90% PABA and related small molecules activate Best1 and can rescue currents for multiple dominant LOF mutants in vitro, suggesting a potential pharmacologic approach for dominant LOF bestrophinopathies.
Falcon reports the Owji et al. (2024) ligand-bound structures and PABA-mediated small-molecule activation as a pharmacologic strategy for dominant LOF mutants.
DOI:10.1038/s41467-024-54938-z
openscientist SILENT —
OpenScientist does not cover the PABA small-molecule channel-activation strategy or the neurotransmitter-bound bestrophin structures.

The electro-oculogram (EOG) — a reduced light peak / Arden ratio — is the hallmark functional diagnostic abnormality, markedly reduced in BVMD and ARB, though a minority of genetically confirmed patients can have a normal EOG.

UNANIMOUS INTEGRATED
diagnosisphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% hallmark reduced light peak / reduced Arden ratio; however normal EOG can occur in a minority (e.g., 8% in one large series).
Falcon names the reduced EOG light peak / Arden ratio as the hallmark and notes it can be normal in a minority (~8%).
openscientist CONCORDANT 88% Gold standard functional test. Measures the Arden ratio (light peak / dark trough). Normal >1.65-1.80; BVMD <1.5; ARB often <1.1.
OpenScientist calls EOG the gold-standard functional test and gives the graded Arden ratio thresholds distinguishing normal, BVMD, and ARB.
PMID:34327816

ARB is distinguished by anterior-segment abnormalities — shallow anterior chamber, narrow angles, and short axial length/hyperopia — conferring angle-closure glaucoma risk and frequent misdiagnosis.

UNANIMOUS INTEGRATED
phenotypediagnosis
ProviderStanceScoreEvidence
falcon CONCORDANT 90% ARB cohort shows frequent shallow anterior chamber/narrow angles; misdiagnosis as angle-closure glaucoma common; preventive iridotomy and glaucoma surgeries used.
Falcon reports the ARB anterior-segment phenotype (shallow chamber/narrow angles), angle-closure misdiagnosis, and preventive iridotomy management.
DOI:10.1186/s12886-024-03574-8
openscientist CONCORDANT 92% Anterior features included shallow anterior chambers (16/17), ciliary pronation (16/17), iris bombe (13/17), iridoschisis (2/17), iris plateau (1/17), narrow angles (16/17) and reduced axial lengths (16/17).
OpenScientist quantifies the ARB anterior-segment features in a Chinese cohort, concordant with the angle-closure predisposition.
PMID:39048936

There is no approved disease-modifying therapy; care is complication-directed, and gene therapy is the leading advanced approach, with preclinical AAV BEST1 augmentation (and CRISPR editing for augmentation-refractory dominant mutants) restoring channel activity and the first human trial (NCT07185256, OPGx-BEST1) underway.

UNANIMOUS INTEGRATED
treatmentprognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Preclinical gene augmentation in canine models shows lesion reversal after subretinal AAV delivery with sustained effects up to
Falcon reports no approved disease-modifying pharmacotherapy, complication-directed care, canine AAV gene-augmentation lesion reversal, and the OPGx-BEST1 (NCT07185256) interventional trial.
DOI:10.4103/sjopt.sjopt_175_23
openscientist CONCORDANT 90% Gene augmentation in iPSC-RPE fully restored BEST1 calcium-activated chloride channel activity and improved rhodopsin degradation in an iPSC-RPE model of recessive bestrophinopathy as well as in two models of dominant Best disease caused by different mutations in regions encoding ion-binding domains.
OpenScientist reports the same lack of approved therapy plus preclinical AAV augmentation (3/4 iPSC-RPE models) with CRISPR rescue of the fourth, and the OPGx-BEST1 Phase 1b/2a trial.
PMID:32707085, PMID:24143172

Narrative

Overview

Both providers frame BEST1 bestrophinopathies as a spectrum of inherited retinal dystrophies caused by variants in BEST1, encoding bestrophin-1, a pentameric calcium-activated chloride channel of the RPE basolateral membrane. The core pathophysiology in both reports is RPE ion/fluid-homeostasis failure producing vitelliform lesions, subretinal fluid, abnormal EOG, and progressive macular degeneration, with dominant-negative dominant forms and loss-of-function recessive forms, no approved therapy, and gene therapy as the emerging intervention.

Agreement

The two reports converge strongly on the molecular defect (bestrophin-1 pentameric Ca2+-activated Cl- channel in RPE), the phenotypic spectrum (BVMD, ARB, ADVIRC, BEST1-RP, adult-onset vitelliform) as a single disease continuum, the dominant-negative-versus-loss-of-function mechanistic split, the RPE downstream causal chain (impaired fluid transport and POS phagocytosis, lipofuscin/vitelliform accumulation, photoreceptor degeneration), the EOG as the hallmark diagnostic, the ARB anterior-segment/angle-closure phenotype, the deep-intronic/founder ARB variants resolved by WGS (c.867+97G>A Chinese founder), and the absence of approved therapy with gene therapy (AAV augmentation, CRISPR editing, NCT07185256 OPGx-BEST1) as the leading advance.

Divergence

The reports diverge mostly by depth and unique detail rather than by conflict. OpenScientist is more comprehensive and quantitative: it enumerates exactly five OMIM-coded phenotypes, gives the largest BVMD natural-history metrics (n=222; ~0.013 logMAR/year), ClinVar variant counts (1,047 total, 693 P/LP), the BEST1-CaV1.3 axis, EMT/NF-kB iPSC-RPE signatures, and — uniquely — the Hsp70/CHIP ubiquitination-at-Lys149 degradation mechanism for p.P233L/p.P346H. Falcon uniquely covers the Owji et al. (2024) ligand-bound bestrophin structures and PABA small-molecule channel-activation strategy that rescues dominant LOF mutants. Falcon also frames adult-onset vitelliform cases as reclassified into BVMD rather than a separate phenotype. No direct contradictions were found; differences are coverage and recency.

Integration

The shared core biology, phenotypic spectrum, dominant-negative/LOF mechanism, RPE causal chain, EOG diagnostic hallmark, ARB anterior-segment phenotype, and gene-therapy landscape are all supported by both providers and align with the existing kb/disorders/BEST1_Bestrophinopathies.yaml entry (channel dysfunction, RPE-photoreceptor interface disruption, subretinal fluid/vitelliform lesions, progressive degeneration).

Not integrated (leads)

The OpenScientist-only Hsp70/CHIP ubiquitination mechanism and the Falcon-only PABA small-molecule activation strategy are retained as single-provider research leads pending primary-literature verification before promotion into curated disease mechanisms.

Cross-provider synthesis of two independent deep-research reports: falcon (Edison Scientific Literature, pathophysiology-template) and openscientist (autonomous, comprehensive 15-domain). best_matching_text values are verbatim excerpts from the cited report files; per the schema, literature evidence snippets are not verified here. The legacy prose roll-up (BEST1_Bestrophinopathies-research-synthesis.md) informed the narrative only and was not quoted as evidence. Two single-provider divergences (Hsp70/CHIP ubiquitination; PABA small-molecule activation) are marked SILENT for the other provider.